Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00763022
First received: September 26, 2008
Last updated: November 8, 2012
Last verified: November 2012
  Purpose

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.


Condition Intervention Phase
Diabetes Mellitus
Drug: TAK-559
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change in Baseline in Glycosylated hemoglobin. [ Time Frame: Weeks: 4, 8, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Baseline in Glycosylated hemoglobin. [ Time Frame: Weeks: 4, 8, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Fasting Plasma Glucose. [ Time Frame: Weeks: 2, 4, 8, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Serum insulin. [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in C-peptide. [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Lipids (triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein). [ Time Frame: Weeks: 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Lipids (low-density lipoprotein fractionation). [ Time Frame: Weeks: 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Apolipoproteins Al and B100. [ Time Frame: Final Visit. ] [ Designated as safety issue: No ]
  • Change in Baseline in Free fatty acids. [ Time Frame: Weeks: 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Markers of thrombosis (plasminogen activator inhibitor-i). [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Markers of thrombosis (fibrinogen). [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Markers of inflammation (interleukin-6). [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Markers of inflammation (C-reactive protein). [ Time Frame: Weeks: 4, 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]
  • Urinary albumin/creatinine ratio. [ Time Frame: Weeks: 12, 16, 20 and Final Visit. ] [ Designated as safety issue: No ]

Enrollment: 302
Study Start Date: November 2003
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAK-559 16 mg QD Drug: TAK-559
TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
Experimental: TAK-559 32mg QD Drug: TAK-559
TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
Placebo Comparator: Placebo QD Drug: Placebo
TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.

Detailed Description:

Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target tissues leads to a decrease in insulin-mediated glucose uptake. Insulin resistance is associated with normal to high insulin levels and is often accompanied by dyslipidemia, a disruption in lipid metabolism resulting in increased triglycerides and low-density lipoprotein levels as well as decreased high-density lipoprotein levels in patients with type 2 diabetes mellitus. In the early stages of insulin resistance, a compensatory mechanism of increased insulin secretion by the pancreas maintains normal to near-normal glucose levels. Once the pancreas fails to maintain the increased insulin output, overt type 2 diabetes mellitus occurs.

TAK-559 is a novel oxyiminoalkanoic acid under investigation for use as an oral agent in the treatment of patients with type 2 diabetes mellitus. TAK-559 has partial peroxisome proliferator-activated receptor-alpha agonist activity, potent peroxisome proliferator-activated receptor-alpha activity, and modest peroxisome proliferator-activated receptor-gamma activity at high concentrations in nonclinical models.

This study was designed to evaluate the safety and glycemic control of TAK-559 in patients with type 2 diabetes mellitus whose symptoms were managed by diet and exercise.

  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is diagnosed with type 2 diabetes mellitus using American Diabetes Association diagnostic criteria, and on a stable dose of an oral anti-diabetic monotherapy prior to Screening A.
  • Had a glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10.0% at Screening B.
  • Had a fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) at Screening B.
  • Was taking a stable dose of at least 10 mg of glyburide for at least 10 days prior to Screening B.
  • Was on a stable or worsening self-monitoring blood glucose level while taking glyburide.
  • Had a low-density lipoprotein less than 160 mg/dL (4.1 mmol/L) at Screening A.
  • Had a body mass index less than or equal to 45 kg/m2 at Screening A.
  • Was willing to be counseled by the investigator or designee to follow an individualized, weight-maintaining diet during the study period.
  • Had evidence of insulin secretory capacity as demonstrated by a C-peptide concentration of greater than or equal to 1.5 ng/mL (0.50 nmol/L) at Screening A, and if necessary, after a repeat at Screening B.
  • Was able to perform daily self-monitoring blood glucose tests throughout the study.
  • Had a normal thyroid-stimulating hormone level of less than 5.5 uIU/mL (5.5 mIU/L) and greater than or equal to 0.35 uIU/mL (0.35 mIU/L) at Screening A.
  • Was in good health as determined by a physician (ie, via medical history and physical examination), other than a diagnosis of type 2 diabetes mellitus.
  • Had fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to Randomization.
  • Females were post menopausal, surgically sterile, or using adequate contraception.

Exclusion Criteria:

  • Was diagnosed with type 1 diabetes mellitus, hemochromatosis, or has a history of ketoacidosis.
  • Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states, hemoglobinopathies).
  • Was required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Insulin
    • Oral anti-diabetics other than TAK-559 (including sulfonylureas other than glyburide, alpha-glucosidase inhibitors, metformin)
    • Systemic corticosteroids
    • Warfarin
    • Rifampin
    • St. John's Wort.
    • Thiazolidinediones
    • Peroxisome proliferator-activated receptor agonists
    • Nicotinic Acid
    • Fibrates
  • Had a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiogram, or documented cerebrovascular accident within 6 months prior to Screening A.
  • Had abdominal, thoracic, or vascular surgery within 6 months prior to Screening A that in the investigator's opinion would warrant exclusion from the study.
  • Had a creatine phosphokinase value greater than 3 times the upper limit of normal at Screening A. The creatine phosphokinase value can be retested prior to Randomization if elevated.
  • Had persistent unexplained microscopic or macroscopic hematuria or a history of bladder cancer.
  • Had a triglyceride level greater than 500 mg/dL (5.6 mmol/L) at Screening A.
  • Had any alteration in allowed lipid lowering medication (dose or drug) within 2 months of Randomization, if applicable.
  • Had donated and/or received any blood or blood products within 3 months prior to Randomization.
  • Had a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within 2 years prior to Randomization.
  • Had a systolic BP greater than 140 mm Hg or a diastolic blood pressure of greater than 95 mm Hg at Screening B.
  • Had significant cardiovascular disease including but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV.
  • Had a previous history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to Randomization.
  • Had an alanine transaminase or aspartate transaminase level greater than 3 times the upper limit of normal, active liver disease, or jaundice at Screening A.
  • Had a positive human immunodeficiency virus, hepatitis B surface antigen, or hepatitis B e antigen test at Screening A.
  • Had any other serious disease or condition at Screening A or at Randomization that might affect life expectancy or make it difficult to successfully manage and follow the patient according to the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00763022

Sponsors and Collaborators
Takeda
Investigators
Study Director: Sr VP Clinical Science Takeda
  More Information

No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00763022     History of Changes
Other Study ID Numbers: 01-02-TL-559-014, U1111-1127-8487
Study First Received: September 26, 2008
Last Updated: November 8, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes
Diabetes Mellitus, Lipoatrophic
Dyslipidemia
Drug Therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 20, 2014